U.S. markets closed
  • S&P Futures

    4,326.75
    -16.50 (-0.38%)
     
  • Dow Futures

    33,694.00
    -104.00 (-0.31%)
     
  • Nasdaq Futures

    14,951.75
    -72.25 (-0.48%)
     
  • Russell 2000 Futures

    2,171.00
    -9.90 (-0.45%)
     
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,773.70
    -4.50 (-0.25%)
     
  • Silver

    22.47
    -0.15 (-0.65%)
     
  • EUR/USD

    1.1722
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    1.3240
    +0.0150 (+1.15%)
     
  • Vix

    24.36
    -1.35 (-5.25%)
     
  • GBP/USD

    1.3655
    -0.0009 (-0.07%)
     
  • USD/JPY

    109.2220
    +0.0020 (+0.00%)
     
  • BTC-USD

    40,720.86
    -1,059.42 (-2.54%)
     
  • CMC Crypto 200

    1,004.49
    -59.36 (-5.58%)
     
  • FTSE 100

    6,980.98
    +77.07 (+1.12%)
     
  • Nikkei 225

    29,700.58
    -139.13 (-0.47%)
     

Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) Nurtec ODT (rimegepant) orally disintegrating tablet (ODT) patients take every other day.

  • Enrolling will start later this year.

  • The primary endpoint will be a 50% reduction in the number of headache days patients experience per month versus Nurtec ODT.

  • Both drugs are designed to target calcitonin gene-related peptide (CGRP), a protein in the brain that's thought to play a key role in migraines, Lilly said.

  • However, Lilly's drug binds to CGRP to prevent it from attaching to receptors, while Biohaven's Nurtec ODT blocks the receptor.

  • Nurtec ODT received approval in May and is the only drug that boasts FDA approvals to prevent and immediately treat migraines.

  • Meanwhile, Emgality is approved to prevent migraines and episodic cluster headaches in adults.

  • Price Action: LLY shares are down 1.37% at 223, and BHVN is down 6.39% at $94.04 during the market trading session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.